

# UCLA

## UCLA Previously Published Works

### Title

Differential pulmonary effects of CoO and La<sub>2</sub>O<sub>3</sub> metal oxide nanoparticle responses during aerosolized inhalation in mice

### Permalink

<https://escholarship.org/uc/item/3g30v9cw>

### Journal

Particle and Fibre Toxicology, 13(1)

### ISSN

1743-8977

### Authors

Sisler, Jennifer D  
Li, Ruibin  
McKinney, Walter  
[et al.](#)

### Publication Date

2015-12-01

### DOI

10.1186/s12989-016-0155-3

Peer reviewed

RESEARCH

Open Access



# Differential pulmonary effects of CoO and La<sub>2</sub>O<sub>3</sub> metal oxide nanoparticle responses during aerosolized inhalation in mice

Jennifer D. Sisler<sup>1</sup>, Ruibin Li<sup>3,4,6</sup>, Walter McKinney<sup>1</sup>, Robert R. Mercer<sup>1</sup>, Zhaoxia Ji<sup>5</sup>, Tian Xia<sup>3,4,5</sup>, Xiang Wang<sup>5</sup>, Justine Shaffer<sup>1</sup>, Marlene Orandle<sup>1</sup>, Amy L. Mihalchik<sup>1</sup>, Lori Battelli<sup>1</sup>, Bean T. Chen<sup>1</sup>, Michael Wolfarth<sup>1</sup>, Michael E. Andrew<sup>1</sup>, Diane Schwegler-Berry<sup>1</sup>, Dale W. Porter<sup>1</sup>, Vincent Castranova<sup>2</sup>, Andre Nel<sup>3,4,5</sup> and Yong Qian<sup>1\*</sup>

## Abstract

**Background:** Although classified as metal oxides, cobalt monoxide (CoO) and lanthanum oxide (La<sub>2</sub>O<sub>3</sub>) nanoparticles, as representative transition and rare earth oxides, exhibit distinct material properties that may result in different hazardous potential in the lung. The current study was undertaken to compare the pulmonary effects of aerosolized whole body inhalation of these nanoparticles in mice.

**Results:** Mice were exposed to filtered air (control) and 10 or 30 mg/m<sup>3</sup> of each particle type for 4 days and then examined at 1 h, 1, 7 and 56 days post-exposure. The whole lung burden 1 h after the 4 day inhalation of CoO nanoparticles was 25 % of that for La<sub>2</sub>O<sub>3</sub> nanoparticles. At 56 days post exposure, < 1 % of CoO nanoparticles remained in the lungs; however, 22–50 % of the La<sub>2</sub>O<sub>3</sub> nanoparticles lung burden 1 h post exposure was retained at 56 days post exposure for low and high exposures. Significant accumulation of La<sub>2</sub>O<sub>3</sub> nanoparticles in the tracheobronchial lymph nodes was noted at 56 days post exposure. When exposed to phagolysosomal simulated fluid, La nanoparticles formed urchin-shaped LaPO<sub>4</sub> structures, suggesting that retention of this rare earth oxide nanoparticle may be due to complexation of cellular phosphates within lysosomes. CoO nanoparticles caused greater lactate dehydrogenase release in the bronchoalveolar fluid (BALF) compared to La<sub>2</sub>O<sub>3</sub> nanoparticles at 1 day post exposure, while BAL cell differentials indicate that La<sub>2</sub>O<sub>3</sub> nanoparticles generated more inflammatory cell infiltration at all doses and exposure points. Histopathological analysis showed acute inflammatory changes at 1 day after inhalation of either CoO or La<sub>2</sub>O<sub>3</sub> nanoparticles. Only the 30 mg/m<sup>3</sup> La<sub>2</sub>O<sub>3</sub> nanoparticles exposure caused chronic inflammatory changes and minimal fibrosis at day 56 post exposure. This is in agreement with activation of the NLRP3 inflammasome after in vitro exposure of differentiated THP-1 macrophages to La<sub>2</sub>O<sub>3</sub> but not after CoO nanoparticles exposure.

**Conclusion:** Taken together, the inhalation studies confirmed the trend of our previous sub-acute aspiration study, which reported that CoO nanoparticles induced more acute pulmonary toxicity, while La<sub>2</sub>O<sub>3</sub> nanoparticles caused chronic inflammatory changes and minimal fibrosis.

**Keywords:** Nanoparticles, Metal oxides, Pulmonary response, In vivo, Mouse

**Abbreviations:** A549, Adenocarcinomic Human Alveolar Base Epithelial Cells; AOPs, Adverse Outcome Pathways; BAL, Bronchoalveolar Lavage; BALF, Bronchoalveolar Fluid; BEAS-2B, Human Epithelial Bronchus Lung Cells; BRP, Biological Redox Potential; Co, Cobalt Monoxide; DNA, Deoxyribonucleic Acid; FESEM, Field Emission Scanning  
(Continued on next page)

\* Correspondence: yaq2@cdc.gov

<sup>1</sup>Health Effects Laboratory Division, National Institute for Occupational Safety and Health, 1095 Willowdale Road, Morgantown, WV 26505, USA  
Full list of author information is available at the end of the article

(Continued from previous page)

Electron Microscope; H&E, Hematoxylin and Eosin; IFN- $\gamma$ , Interferon-gamma; IL-10, Interleukin-10; IL-12p70, Interleukin-12; IL-1 $\beta$ , Interleukin-1beta; IL-2, Interleukin-2; IL-4, Interleukin-4; IL-5, Interleukin-5; IL-6, Interleukin-6; INAA, Instrumental Neutron Activation Analysis; KC/GRO, Neutrophil-Activating Protein 3; La<sub>2</sub>O<sub>3</sub>, Lanthanum oxide; LDH, Lactate Dehydrogenase; LPS, Lipopolysaccharide; MMADs, Mass Median Aerodynamic Diameter; MPPD, Multiple-Path Particle Dosimetry; MT3, Metallothionein 3; NIOSH, National Institute for Occupational Safety and Health; NOS2, Nitric Oxide Synthase 2; NLRP3 NLR, Family Pyrin Domain Containing 3; PBS, Phosphate-Buffered Saline; PDGF, Platelet-Derived Growth Factor; PMA, Phorbol 12-Myristate Acetate; PMNs, Polymorphonuclear Leukocyte; PSF, Phagolysosomal Simulated Fluid; PSR, Picosirius Red; PTG2(COX2), Prostaglandin-Endoperoxide Synthase 2; RAW264.7, Mouse Macrophage Cells; REL, Recommended Exposure Limit; ROS, Reactive Oxygen Species; SAEC, Small Airway Epithelial Cells; SOD3, Superoxide Dismutase 3; TEM, Transmission Electron Microscopy; THP-1, Human Monocytic Cells; TiO<sub>2</sub>, Titanium Dioxide; TNF $\alpha$ , Tumor Necrosis Factor-Alpha; XRD, X-Ray Diffraction

## Background

Nanotechnology is perceived as one of the most notable research achievements of this century. Engineered nanoparticles are currently being used in many industrial areas. Particularly, metal oxide nanoparticles are an important class of engineered nanomaterials with broad applications in many industries. From a health perspective, previous studies have shown that some metal oxide nanoparticles can induce adverse effects at organ, tissue, cellular, protein, and gene levels [1]. A number of transition metal oxide nanoparticles exhibit semi-conductor properties in which the material band gap plays a role in electron transfer to and from biological redox components. This can lead to the generation of adverse health effects due to the generation of oxygen radicals and oxidative stress [2]. According to the band gap theory, electron transfer between metal oxide nanoparticles and aqueous biological reactants is dependent on an overlap of the metal oxide band gap energy level with a biological equivalent, known as the cellular redox potential [3]. The accompanying electron transfer from the nanoparticle surface to a series of redox couples that reconstitute of biological redox potential can result in the generation of reactive oxygen species (ROS), disturbance of cellular redox homeostasis, and oxidative damage to DNA or proteins [4, 5]. Cobalt monoxide (CoO) and lanthanum oxide (La<sub>2</sub>O<sub>3</sub>) differ with respect to their biological properties. While for the transition metal oxide, CoO, the conduction band energy overlaps with the cellular biological redox potential, there is no similar overlap for the rare earth oxide, La<sub>2</sub>O<sub>3</sub> [3]. In contrast, La<sub>2</sub>O<sub>3</sub> (and other rare earth oxide) nanoparticles exhibit non-oxidative surface reactivity that may come into play in a biological environment with the possibility to generate hazard through complexation of cellular phosphate groups in the lysosome [6]. In brief, this study addresses how phosphate complexation of La nanoparticles in the acidic environment of the phagolysosome can induce lysosomal membrane damage, activation of the NLRP3 inflammasome, and IL-1 $\beta$  production [6].

Previously, we investigated CoO and La<sub>2</sub>O<sub>3</sub> nanoparticle-induced cellular toxicity, production of superoxide radicals, and alterations in gene expression related to oxidative stress and cellular death in human small airway epithelial cells (SAEC) [7]. Results in that study showed that CoO nanoparticles caused more adverse effects than La<sub>2</sub>O<sub>3</sub> nanoparticles, using cytotoxicity assays in SAEC. Moreover, CoO nanoparticles produced more superoxide radicals and induced greater induction of total global tyrosine and threonine phosphorylation in SAEC compared to the La<sub>2</sub>O<sub>3</sub> nanoparticle. Profiling of oxidative stress pro-apoptotic gene expression demonstrated that CoO nanoparticles induced significant transcriptional activation of PTGS2(COX2), NOS2, SOD3, and MT3 genes in SAEC. These results indicate that different modes of action could be involved in mediating cellular toxicity by CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles. Similar observations regarding the cytotoxic potential of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles have been reported by other laboratories. For instance, CoO nanoparticles have been shown to be cytotoxic in human lymphocytes, alveolar A549, and bronchial BEAS-2B epithelial cells [8, 9]. However, Lim et al. showed that La<sub>2</sub>O<sub>3</sub> nanoparticles were cytotoxic at high doses and prolonged exposure times in RAW264.7 and A549 cells [10]. In addition, our recent study indicates that La<sub>2</sub>O<sub>3</sub> nanoparticles (50  $\mu$ g/mL) induced lysosomal damage, cathepsin B release, and IL-1 $\beta$  production after in vitro exposure of differentiated THP-1 macrophages for 6 h [6]. Taken together, these data demonstrate that CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles have the potential to induce different biological effects in vivo, based on different modes of action after pulmonary exposure. For instance, in oropharyngeal aspiration studies in mice, we observed more acute inflammation with CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles which is in agreement with in vitro cytotoxicity results [3]. However, in a longer term (21 day post exposure) La<sub>2</sub>O<sub>3</sub> aspiration study, we observed elevation of fibrogenic factors in bronchoalveolar lavage fluid (BALF) and increased lung collagen in mice; which is in agreement with in vitro

activation of the NLRP3 inflammasome in cellular studies [6].

The objective of the present study was to explore the pulmonary effects of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles in mice for up to 56 days after whole-body inhalation exposure, which is more representative of possible human exposures than a bolus dose administration. The rationale for this study was to determine whether the different modes of action of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles could be seen to elicit different types of information after short and longer-term exposure as a reflection of the effect of the bandgap overlap and pro-oxidative properties of the former particle type versus activation of the NLRP3 inflammasome by La<sub>2</sub>O<sub>3</sub> nanoparticles.

BALF and pulmonary tissue were analyzed to determine if these nanomaterials have overlapping or contrasting features that can be related to inhalation exposure at low and high doses. We demonstrate that there are indeed differences in the pulmonary responses to CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles in the induction of acute vs. chronic pulmonary responses. Such differences are reflective of adverse outcome pathways (AOPs) for these materials [11], which we previously established by our cellular and bolus aspiration studies [3, 6, 7]. The results of this inhalation study support the usefulness of a tiered approach including mechanistically relevant in vitro screening tests and bolus in vivo exposures in predicting pulmonary responses during inhalation exposures to nanoparticles [11].

## Methods

### Nanoparticles

CoO nanoparticles were purchased from SkySpring Nanomaterials (Houston, TX) and La<sub>2</sub>O<sub>3</sub> nanoparticles were purchased from Nanostructured & Amorphous Materials, Inc. (Houston, TX). The physicochemical characteristics of these particles are given in Table 1 [3, 7].

### Acellular transformation of La<sub>2</sub>O<sub>3</sub> nanoparticles in phagolysosomal simulated fluid (PSF)

La<sub>2</sub>O<sub>3</sub> nanoparticles were suspended in 10 mL of phagolysosomal simulated fluid (PSF) (142 mg/L Na<sub>2</sub>HPO<sub>4</sub>, 6.65 g/L NaCl, 62 mg/L Na<sub>2</sub>SO<sub>4</sub>, 29 mg/L CaCl<sub>2</sub> • 3

H<sub>2</sub>O, 250 mg/L glycine, 8.09 g/L potassium phthalate, pH 4.5) at a concentration of 50 µg/mL, and sonicated at 32 W for 15 s. Following incubation at 37 °C for 24 h, the particle suspensions were centrifuged at 15,000 rpm for 10 min. The pellets were collected, thoroughly washed with DI H<sub>2</sub>O and dried for further use. The composition and morphology of PSF-treated La<sub>2</sub>O<sub>3</sub> nanoparticles were characterized by XRD (Panalytical X'Pert Pro diffractometer, Cu KR radiation) and TEM (JEOL 1200 EX, accelerating voltage 80 kV), respectively.

### Cathepsin B release and IL-1β production in THP-1 cells

THP-1 cells were differentiated into macrophages as described previously [6]. Briefly, aliquots of 5 × 10<sup>4</sup> cells were seeded in 0.1 mL complete medium and primed with 1 µg/mL of phorbol 12-myristate acetate (PMA) overnight in 96-well plates (Corning; Corning, NY, USA). These macrophages were treated with CoO or La<sub>2</sub>O<sub>3</sub> nanoparticles (50 µg/mL) in complete RPMI 1640 for 6 h, followed by washing in phosphate-buffered saline (PBS). Cells were stained with the cathepsin B substrate, Magic Red (ImmunoChemistry Technologies), for 1 h and fixed in 4 % paraformaldehyde for 20 min. Following washing in PBS, nuclei were stained with Hoechst 33342 for 1 h. The cells were visualized under a confocal microscope (Leica Confocal SP2 1P/FCS). High magnification images were obtained under the 63× objective and the lysosomal vs. cytosolic staining of cathepsin B noted as an indication of particle-induced lysosomal damage.

IL-1β production was detected in the THP-1 differentiated macrophage culture medium, using a human IL-1β ELISA Kit (BD; San Jose, CA, USA). Briefly, cells (5 × 10<sup>4</sup> cells) were treated with 0 – 100 µg/mL CoO or La<sub>2</sub>O<sub>3</sub> nanoparticles suspended in complete RPMI 1640 that also contained 10 ng/mL of lipopolysaccharide (LPS) to induce production of pro-IL-1β. The nanoparticle suspensions were sonicated in media containing 10 % fetal bovine serum with a Sonics & Materials probe at 32 W for 15 s before adding to the cells. As reported previous studies [3], acellular suspensions of CoO nanoparticles generated significant levels of reactive oxygen species (ROS) measured as DCF fluorescence. ROS generation was not affected by sonication (Additional file 1: Figure S1). In contrast, suspensions of La<sub>2</sub>O<sub>3</sub> nanoparticles did not generate ROS either before or after sonication (Additional file 1: Figure S1). It should be noted that the densities of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles and their resultant sedimentation rates in cell culture media are similar. Calculations indicate that 80 % of the nanoparticles would settle on the cells after 24 h.

### Animals

Eight week old male, pathogen-free C57BL/6 J mice were obtained from Jackson Laboratories (Bar Harbor, ME).

**Table 1** Physicochemical Characterization of CoO and La<sub>2</sub>O<sub>3</sub> Nanoparticles

Property	Characterization Technique	Nanoparticles	
		CoO	La <sub>2</sub> O <sub>3</sub>
Size	TEM	72 ± 16 nm	25 ± 5 nm
Crystal Structure	XRD	Cubic	Hexagonal
Morphology	TEM	Agglomerate	Agglomerate
Size in DI H <sub>2</sub> O	DLS	185 ± 12 nm	211 ± 11 nm
Zeta potential in DI H <sub>2</sub> O	Zeta PALS	32 ± 4 mV	58 ± 7 mV

Mice were housed individually and allowed to acclimate for 1 week in an AAALAC-accredited animal facility and 4 days within the chambers, which were used later for whole-body inhalation exposure. After exposure, animal weight was monitored weekly to assess the health of the animals. All procedures performed on animals were approved by the NIOSH Institutional Animal Care and Use Committee (IACUC).

Mice were assigned to exposure groups using a randomized complete block design. Mice were exposed to either CoO or La<sub>2</sub>O<sub>3</sub> nanoparticles, or air control. Mice were used to determine whole lung deposition immediately post exposure, lung clearance, inflammatory and damage markers in bronchoalveolar lavage, or histopathologic responses. Animals were exposed to a low dose (10 mg/m<sup>3</sup>) or high dose (30 mg/m<sup>3</sup>) for 4 days at 6 h/day and were sacrificed at 1 h and 1, 7, or 56 days post exposure. At 1 h post exposure, animals were taken for lung burden ( $n = 5$  mice per each CoO and La<sub>2</sub>O<sub>3</sub> exposure group and air control). At 1, 7, and 56 days post exposure, animals were analyzed for bronchoalveolar lavage and histopathology ( $n = 12$  for each CoO and La<sub>2</sub>O<sub>3</sub> exposure group and  $n = 24$  for air control). At 56 days post exposure, mice were taken for analysis of nanoparticle clearance from the mouse lung ( $n = 5$  mice per each CoO and La<sub>2</sub>O<sub>3</sub> nanoparticle exposure group).

#### Inhalation exposure system

The CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles aerosols were generated using an acoustical-based, computer controlled, whole body inhalation system as described previously [12]. In brief, the inhalation exposure system combines air flow controllers, aerosol particle monitors, data acquisition devices, and custom software with automated feedback control to achieve constant and repeatable exposure chamber temperature, relative humidity, pressure, aerosol concentration, and particle size distributions as previously described [12–15]. The system is capable of producing airborne particles continuously for long periods of time with minimal fluctuations.

In this study, the CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles aerosol mass concentrations within the exposure chamber were continuously monitored with a Data RAM (DR-40000 Thermo Electron Co, Franklin, MA), and gravimetric determinations (37 mm cassettes with 0.45  $\mu$ m pore-size Teflon filters) were used to calibrate and verify the Data RAM readings each day. The target concentrations for both CoO and La<sub>2</sub>O<sub>3</sub> were 10 mg/m<sup>3</sup> for a duration of 6 h/day for 4 consecutive days (low dose), or 30 mg/m<sup>3</sup> for a duration of 6 h/day for 4 consecutive days (high dose). These aerosol concentrations and exposure durations were chosen to yield lung burdens in the range of our previous aspiration study [6]. Each exposure

group had a corresponding clean air control exposed group.

The mass-based particle size distribution of the nanoparticle aerosol in the exposure chamber was determined by a cascade impactor (MOUDI Model 110-R, MSP Corp., Shoreview, MN). Exposure chamber air (10 L/min) was mixed with filtered air (20 L/min) and fractionated onto 10 size stages of the impactor, representing 10 size ranges from 56 nm to 18  $\mu$ m. Mass median aerodynamic diameter was obtained from these data.

The count-based particle size distribution of particles within the exposure chamber was measured using a Scanning Mobility Particle Sizer (SMPS model, TSI Inc., Shoreview, MN) at a sampling rate of 0.3 L/min. Count median aerodynamic diameter was obtained from these data assuming a spherical particle shape.

Aerosol samples from the exposure chamber were collected on 25 mm polycarbonate filters with 0.2  $\mu$ m pores (EMD-Millipore, Billerica, MA) at a rate of 1 L/min to obtain particle samples for further analysis by field emission scanning electron microscopy (FESEM) as described previously [12, 14].

#### Lung burden and lung clearance

Mice were euthanized after 1 h or 56 days post-exposure by intraperitoneal (i.p.) injection of sodium pentobarbital and exsanguination. The 1 h analysis time was included to determine lung burden immediately following the 4 day inhalation exposure. This would provide information concerning the rapid clearance of particles from the conducting zone during the 4 days of inhalation exposure. The differences in lung burden from 1 h to 56 days post exposure would provide information concerning the slow phase of clearance. Lungs with associated lymph nodes (whole lungs) were harvested from nanoparticle-exposed mice, as well as, ambient air control mice, snap frozen in liquid nitrogen, and stored at  $-80$  °C. CoO or La<sub>2</sub>O<sub>3</sub> nanoparticle lung burden was determined by Elemental Analysis, Inc. (Lexington, KY) using instrumental neutron activation analysis (INAA). Briefly, lung samples were exposed to a thermal neutron flux of  $5 \times 10^3$  n/cm<sup>2</sup>/s for 24 h to produce radioactive Co or La. The radioactive emission from the samples was measured by gamma-ray spectroscopy. The intensity of emissions for these lung samples was compared to spiked samples and is indicative of the amount of the Co or La present in the lung.

#### Bronchoalveolar lavage

At 1, 7 and 56 days post exposure, mice were euthanized by i.p. injection of sodium pentobarbital ( $>100$  mg/kg body weight). These post exposure times were chosen to determine if lung damage and inflammation were transient or more prolonged as determined by markers in bronchoalveolar lavage (BAL) samples as described



previously [14]. BAL of the whole lung was performed by inserting a cannula into the trachea and lavaging with  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  free phosphate-buffered saline, pH 7.4 with the addition of 0.55 mM D-glucose (PBS). The initial whole lung lavage was performed twice using 0.6 mL PBS. The subsequent lavages were performed using a 1 mL aliquot per lavage until a total collection volume of 4 mL PBS was obtained. BAL cells were collected through centrifugation ( $1,500 \times g$ , 5 min, 4 °C) of the first and subsequent lavages, cell pellets were combined, washed with 1 mL PBS, and centrifuged ( $1,500 \times g$ , 5 min, 4 °C). BAL cells were re-suspended with 250  $\mu\text{L}$  PBS and total cell counts were determined using a Coulter Counter (Multisizer 4, Beckman Coulter, Brea CA). Cytospins of the BAL cells were generated using a Shandon cytospin 4 (Thermo Fisher, Waltham, MA) and stained with modified Wright stain (Thermo Fisher, Waltham, MA). Cytospins were analyzed for cell differentials using an Olympus DP73 light microscope (Tokyo, Japan) and analyzed using the Olympus CellSens Dimension program (Tokyo, Japan). A total of 200 cells per slide were counted. The total number of each cell type was determined from total cell counts previously determined. The supernatant of the first lavage was collected after centrifugation and used for lactate dehydrogenase (LDH) levels and cytokine/chemokine analysis.

#### **BAL fluid LDH measurement**

BAL fluid (BALF) was analyzed for lactate dehydrogenase (LDH) activity, a measure of cytotoxicity, using a COBAS MIRA Plus (Roche Diagnostic Systems, Montclair, NJ) as previously described [14]. Samples (never frozen) were assayed via manufacturer's protocol where the chemical oxidation of LDH to pyruvate coupled with the reduction of  $\text{NAD}^+$  was measured at 340 nm.

#### **BAL fluid cytokine and chemokine measurement**

BALF from 1, 7, and 56 post exposure day mice was used to analyze cytokine and chemokine expression as previously described [14] with the following modifications. Samples were processed with the V-Plex pro-inflammatory Panel (mouse) kit (Meso Scale Discovery, Gaithersburg, MD) using the manufacturer guidelines. Samples were run in duplicate. The following cytokine/chemokines were analyzed: interferon gamma ( $\text{IFN-}\gamma$ ), interleukin-10 (IL-10), interleukin-12 (IL-12p70), interleukin-1 beta (IL-1 $\beta$ ), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), neutrophil-activating protein 3 (KC/GRO), and tumor necrosis factor-alpha (TNF $\alpha$ ).

#### **Fixation and sectioning of lung tissue**

At 1, 7, and 56 days post exposure, mice from the 10 and 30  $\text{mg}/\text{m}^3$  groups were euthanized by an i.p.

injection with sodium pentobarbital ( $>100$  mg/kg body weight) followed by exsanguination. These time points provide histopathological information concerning the time course of particle-induced inflammation. The slow development of fibrosis would be evaluated by collagen staining of lung tissue at 56 days post exposure. The left lung was inflated with 0.5 mL 10 % neutral buffered formalin. Tracheobronchial lymph nodes were taken from 1 and 56 day post exposure mice from the air control and 30  $\text{mg}/\text{m}^3$  CoO or La<sub>2</sub>O<sub>3</sub> nanoparticle groups and fixed with 10 % neutral buffered formalin. Sections of the left lung and the tracheobronchial lymph nodes were processed, embedded in paraffin, cut at 5 microns and stained with hematoxylin and eosin (H&E) for microscopic analysis. Sections of the left lung were also stained with Masson's trichrome and Sirius red for fibrosis evaluation. Stained slides were sent to Integrated Laboratory Systems, Inc. (Research Park Triangle, NC) for histopathological analysis. Results were peer reviewed by a veterinary pathologist at NIOSH (Morgantown, WV). Images were captured using an Olympus BX53 microscope equipped with a DP73 camera.

#### **Enhanced-darkfield light microscopy imaging of nanoparticles**

CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles in sections from exposed lungs and tracheobronchial lymph nodes were assessed using an enhanced-darkfield optical system as described previously [14]. Although these nanoparticles have dimensions less than the wavelength of light, they have closely packed atoms, and thus typically have a refractive index significantly different from that of biologic tissues and/or mounting medium. These characteristics produce significantly greater scattering of light by nanoparticles, which then appear as bright particles compared to the surrounding tissues. As described previously, this method of imaging can be used to scan lung sections at relatively low magnification to identify nanoparticles that would not be detected by other means [13–16].

The optical system for detection of nanoparticles consisted of high signal-to-noise, darkfield-based illumination optics adapted to an Olympus BX-41 microscope (CytoViva, Auburn, AL). Sections for darkfield examination were specifically cut from paraffin blocks and collected on ultrasonically cleaned, laser cut slides (Schott North America Inc, Elmsford, NY) to avoid nanoparticle contamination from the ground edges of traditional slides. After staining with Sirius red-hematoxylin, sections were coverslipped with Permount. After alignment of the substage oil immersion optics with a 10 $\times$  objective, sections were examined with 60 $\times$  air or 100 $\times$  oil immersion objectives. Enhanced darkfield images were taken with a 2048  $\times$  2048 pixel digital camera (Dage-MTI Excel digital camera XLMCT, Michigan City, IN).

**Statistics**


Statistical comparisons for CoO and La<sub>2</sub>O<sub>3</sub> nanoparticle exposed groups, separately, across three concentrations including air controls were performed separately for each of three post exposure times using analysis of variance (ANOVA). Since variance estimates were different across treatment groups, the ANOVA models were estimated using an unequal variance method available from SAS PROC MIXED [17]. Similarly, comparisons across exposure times for each concentration were performed using unequal variance ANOVA. All statistical tests were two tailed with the significance level set to 0.05.

**Results**

**Aerosol particle characterization**

Exposure chamber aerosol samples were collected by drawing particles from the chamber through several

aerosol instruments. The mass median aerodynamic diameters of the CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles were determined by a cascade impactor (MOUDI Models 110-R, MSP Corp, Shoreview, MN), which fractionates the particles into 10 size ranges from 56 nm to 18 μm. Results are depicted in Fig. 1a and b. The mass median aerodynamic diameter of CoO nanoparticles was determined to be 2.16 μm with a geometric standard deviation of 2.95. The mass median aerodynamic diameter of La<sub>2</sub>O<sub>3</sub> nanoparticles was determined to be 2.26 μm with a geometric standard deviation of 2.02. The count median aerodynamic diameters of the CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles were measured using a Scanning Mobility Particle Sizer (SMPS model, TSI Inc, Shoreview, MN). These data are depicted in Fig. 1c and d. The median mobility equivalent diameter was 259 nm for CoO nanoparticles and 348 nm for La<sub>2</sub>O<sub>3</sub> nanoparticles, with geometric



**Fig. 1** Aerosol particle characterization. Mass median aerodynamic diameter of **a** CoO and **b** La<sub>2</sub>O<sub>3</sub> nanoparticles measured by a cascade impactor (MOUDI). Count median aerodynamic diameter of **c** CoO and **d** La<sub>2</sub>O<sub>3</sub> nanoparticles measured by a scanning mobility particle sizer. FESEM of aerosolized **e** CoO and **f** La<sub>2</sub>O<sub>3</sub> nanoparticles from the whole-body inhalation chamber


standard deviation of 1.65 nm and 1.53 nm for CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles, respectively. Aerosol samples were collected on 25 mm polycarbonate filters with 0.2 μm diameter pores (EMD-Millipore, Billerica, MA) at a rate of 1 L/min. Particle imaging was performed using these filter samples of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles with a field emission scanning electron microscope (FESEM; JEOL 6400, JEOL Inc) (Fig. 1e and f, respectively).

**Lung burden and clearance of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles**

Lungs, consisting of the lower trachea, lung lobes and lymph nodes, were analyzed to determine the whole lung burden of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles by INAA at 1 h after completion of the inhalation exposure. As seen in Fig. 2, mice exposed to CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles at 10 mg/m<sup>3</sup> had an initial whole lung burden of 7.7 μg/lung and 30.1 μg/lung, respectively. At 30 mg/m<sup>3</sup>, CoO nanoparticle-exposed mice had a whole lung burden at 1 h post exposure of 18.7 μg/lung, while La<sub>2</sub>O<sub>3</sub> nanoparticle-exposed mice had a whole lung burden of 77.5 μg/lung 1 h after exposure. To determine nanoparticle clearance, whole lungs from mice exposed to the low or high particle doses were examined at 56 days post exposure. CoO nanoparticles were rapidly cleared, to the extent that <1 % of the nanoparticles remained in the lung plus lymph nodes at both exposure concentrations. However, for La<sub>2</sub>O<sub>3</sub> nanoparticles, 22 and 50 % of the particles remained in the lung and lymph nodes 56 days after low and high dose exposures to La<sub>2</sub>O<sub>3</sub> nanoparticles, respectively. These data indicate considerable differences in the rate of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticle clearance.


To further investigate the lung burden and clearance of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles, enhanced-darkfield

light microscopy was used to analyze the lungs and tracheobronchial lymph nodes for nanoparticle deposition and accumulation in lymph nodes in mice exposed at 30 mg/m<sup>3</sup>. CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles were present in the lung tissue at 1 day post exposure (Fig. 3). An equal amount of La<sub>2</sub>O<sub>3</sub> nanoparticles was found in the alveolar macrophages when compared to the CoO nanoparticles; however, more La<sub>2</sub>O<sub>3</sub> nanoparticles were seen in the interstitium at 1 day post exposure, reflecting a higher lung burden 1 h post exposure and more translocation of La<sub>2</sub>O<sub>3</sub> nanoparticles. These data correlated with the whole lung burden results measured by INAA, indicating greater clearance of CoO nanoparticle than the La<sub>2</sub>O<sub>3</sub> nanoparticles. Therefore, the tracheobronchial lymph nodes were analyzed (Fig. 4). Results showed that the lymph nodes had no CoO nanoparticles, but showed some scattered La<sub>2</sub>O<sub>3</sub> nanoparticles at 1 day post exposure. Furthermore, the lymph nodes of mice exposed to La<sub>2</sub>O<sub>3</sub> nanoparticles at 56 days post exposure showed abundant nanoparticles, supporting migrating of La particles from the interstitium to the lymphatics. In contrast, the lymph nodes of only 2 of the 5 animals examined showed a few scattered CoO nanoparticles at 56 days post exposure. In the conducting airways, it was observed that the CoO nanoparticles were cleared very rapidly (data not shown), while the La<sub>2</sub>O<sub>3</sub> nanoparticles accumulated in the airway epithelium at 1 day post exposure for the high-dose exposure group (Fig. 5). Therefore, CoO nanoparticles depositing on the conducting airways appear to be cleared rapidly during the 4 day inhalation exposure by the mucociliary escalator, while La<sub>2</sub>O<sub>3</sub> nanoparticles clearance from the conducting airways are inhibited by rapid uptake by airway epithelial cells. These enhanced darkfield results support the



**Fig. 2** Whole lung burden and clearance of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles. Lungs and associated lymph nodes from mice were analyzed by INAA for initial whole lung burden (1 h post exposure on day 4) and lung clearance (56 days post exposure) for CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles at 10 and 30 mg/m<sup>3</sup>. Values are presented as μg of nanoparticle per weight of lung. n = 5 male mice per group. \*p < 0.05 represents significance between air control and CoO or La<sub>2</sub>O<sub>3</sub> nanoparticle-exposed mice. # p < 0.05 represents significance between CoO and La<sub>2</sub>O<sub>3</sub> nanoparticle-exposed mice





**Fig. 3** Enhanced-darkfield images-lung deposition. Representative images of lungs from mice 1 and 56 days after exposure to 30 mg/m<sup>3</sup> illustrate the lung burden and clearance of nanoparticles from the lung. *n* = 6 male mice per group. Nanoparticles are identified by white arrows

INAA data showing that the whole lung burden of CoO nanoparticles 1 h post exposure is lower than that of La<sub>2</sub>O<sub>3</sub> nanoparticles. Additionally, La<sub>2</sub>O<sub>3</sub> nanoparticles appear to translocate to tracheobronchial lymph nodes, resulting in relatively high whole lung burdens at 56 days post exposure.


**Transformation of La<sub>2</sub>O<sub>3</sub> nanoparticles in phagolysosomal simulated fluid (PSF)**

As we reported previously, exposure of differentiated THP-1 macrophages to La<sub>2</sub>O<sub>3</sub> nanoparticles (50 µg/ml) resulted in engulfment and incorporation of these nanoparticles into phagolysosomal vesicles after 6 h in culture [6]. Suspension of La<sub>2</sub>O<sub>3</sub> nanoparticles in an acidic PSF for 24 h resulted in a change in nanoparticle morphology from spheres to a sea-urchin-like shape (Fig. 6a). This morphological transformation is associated with a chemical modification of the nanoparticle from La<sub>2</sub>O<sub>3</sub> to LaPO<sub>4</sub> as determined by XRD (Fig. 6b). In contrast, CoO nanoparticles do not undergo phosphate complexation and do not undergo transformation. We have previously demonstrated that La<sub>2</sub>O<sub>3</sub> nanoparticles undergo


similar transformation in the lung [6] and proposed that the accompanying insolubility of the LaPO<sub>4</sub> may be responsible for slow clearance of these particles, allowing their translocation across the epithelial layer to the interstitium and from there to the regional lymph nodes.

**Pulmonary damage and inflammation**

LDH activity in BALF was used as a measure of nanoparticle-induced pulmonary damage at days 1, 7 and 56 post exposure. Figure 7a shows that CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles induce significant LDH release at 1 and 7 days post-exposure compared to the air-only control, but returned to basal levels by 56 days post exposure for both low- and high-dose exposures. When comparing CoO and La<sub>2</sub>O<sub>3</sub>, CoO nanoparticles resulted in significantly higher LDH levels 1 day after the 10 mg/m<sup>3</sup> exposure than La<sub>2</sub>O<sub>3</sub> nanoparticles. However, there were no further differences between these nanoparticles for low-dose exposures at all other post-exposure times. When comparing the impact of high-dose exposures, CoO nanoparticles significantly increased LDH levels at 1 day post exposure compared to La<sub>2</sub>O<sub>3</sub> nanoparticles,





**Fig. 4** Enhanced-darkfield images- tracheobronchial lymph nodes. Representative images of tracheobronchial lymph nodes from mice 1 and 56 days post exposure to 30 mg/m<sup>3</sup> illustrate the initial lung burden and accumulation of nanoparticles in the tracheobronchial lymph nodes. *n* = 6 male mice per group. Nanoparticles are identified by white arrows



but this position was reversed at 7 days post exposure, when La<sub>2</sub>O<sub>3</sub> nanoparticles induced greater LDH release compared to CoO nanoparticles. There were no significant differences between nanoparticle-exposed groups and the air control at 56 days post inhalation for both low and high exposure levels.

Pulmonary inflammation was determined as polymorphonuclear leukocytes (PMNs) calculated from total BAL cell counts and cell differentials of BAL samples from exposed mice. As seen in Fig. 7b, PMNs were significantly elevated at 1 and 7 days post exposure for low-dose exposure to both particle types compared to the air-only control. While the PMNs cell count was higher in La<sub>2</sub>O<sub>3</sub> nanoparticles compared to CoO nanoparticle-exposed animals at 1 and 7 days post exposure, the counts returned to background levels at 56 days post-exposure. The same pattern was seen for high-dose exposures on days 1 and 7 days post exposure. However, 56 days after the high-dose La<sub>2</sub>O<sub>3</sub> nanoparticles exposure, a significant increase in the BALF PMNs





cell counts persisted when compared to the air-only control. This was not the case for high-dose exposure to CoO nanoparticles. Figure 7c indicates that there were increased numbers of alveolar macrophages during low-dose exposure to both particle types at day 1 and 7 post-exposure, as well as, after 1, 7 and 56 days following exposure to 30 mg/m<sup>3</sup> to both particle types. When comparing the number of alveolar macrophages in CoO and La<sub>2</sub>O<sub>3</sub> nanoparticle-exposed


BAL samples, La<sub>2</sub>O<sub>3</sub> nanoparticles had significantly higher counts at 1 and 7 day post exposure at the low exposure and at 1 and 56 day after the higher exposure level. Figure 7d demonstrates that low-dose CoO nanoparticles exposure induced higher lymphocyte cell counts at 1 day post exposure, as well as, on days 1 and 7 following high-dose exposure. La<sub>2</sub>O<sub>3</sub> nanoparticles induced increased lymphocyte cell counts on days 1 and 7 after low-dose exposure and

on days 1, 7 and 56 after high-dose exposure. CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles also induced elevated eosinophils levels on days 1 and 7 following both low-and high-dose exposures. Eosinophils levels remained elevated 56 days after high-dose La<sub>2</sub>O<sub>3</sub> nanoparticles exposure (Fig. 7e). When contrasting the induction of eosinophils between CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles, it was determined that La<sub>2</sub>O<sub>3</sub> nanoparticles induced higher counts at days 1 and 7 in response to low-dose exposure, as well as 1 and 56 days after high-dose exposure. In summary, these data indicate that while both CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles induced acute pulmonary inflammation, only La<sub>2</sub>O<sub>3</sub> nanoparticles induced a chronic inflammatory response with an increased recruitment of a spectrum of inflammatory cells when compared to both air control and CoO nanoparticle-exposed mice.


**CoO and La<sub>2</sub>O<sub>3</sub> nanoparticle-induced cytokine production**

Ten different cytokines were examined in the BALF of mice exposed to low and high doses of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles, and sacrificed at 1, 7 and 56 days post exposure. Four cytokines showed significant differences from the air-only control. This includes increased release of IL-1β in the BALF on days 1 and 7 after high-dose exposure to both nanoparticle types (Fig. 8a). IL-1β levels were higher 1 day after CoO nanoparticles exposure compared to La<sub>2</sub>O<sub>3</sub> nanoparticles. However, the opposite was seen after 7 days, with La<sub>2</sub>O<sub>3</sub> nanoparticles inducing the greater response. After 56 days, there were no increases in IL-

1β levels for either nanoparticle type. In order to elucidate the possible explanation for the differences in sustained in vivo IL-1β production in response to the different particle types, we performed an in vitro study with differentiated THP-1 macrophages. We have previously demonstrated that upon differentiation of this myeloid cell line, THP-1 cells attain macrophage-like properties. Therefore, differentiated THP-1 macrophages have commonly been used to assess responses of pulmonary macrophages to a number of engineered nanoparticles. Since both CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles have been shown by our lab to be engulfed by differentiated THP-1 macrophages and become associated with phagolysosomes [6], we assessed whether there is a difference in their ability to induce lysosomal damage by using a Magic Red-labeled substrate for the lysosomal enzyme, cathepsin B. As shown in Fig. 9a, both non-treated, as well as, CoO nanoparticle-treated cells exhibit a punctate distribution of Magic Red, which is confined to intact lysosomes. However, in the case of La<sub>2</sub>O<sub>3</sub> nanoparticle-treated cells, the dye could be seen to spread diffusely to the cytosol, indicating lysosomal damage. Lysosomal damage, as well as the release of cathepsin B are known stimuli that lead to the assembly of the NLRP3 inflammasome, which is responsible for cleavage of pre-IL-1β to IL-1β. Accordingly, we also found that in vitro exposure to La<sub>2</sub>O<sub>3</sub> nanoparticles induced a significant increase in IL-1β production compared to CoO nanoparticles, which induced little effect (Fig. 9b).








TNFα (Fig. 8b) was significantly elevated at 1 and 7 days post exposure for both nanoparticle types at low and high doses, compared to the air-only control. Moreover, the levels remained higher than control for up to 56 days following the high-dose La<sub>2</sub>O<sub>3</sub> nanoparticles exposure. La<sub>2</sub>O<sub>3</sub> nanoparticles induced higher TNFα level than CoO nanoparticles 1 day after low-dose exposure and 7 days after high-dose exposure. IL-6 (Fig. 8c) was increased at 1 day after the low-dose exposure and days 1 and 7 following high-dose exposure for both nanoparticle types. CoO nanoparticles induced a bigger response than La<sub>2</sub>O<sub>3</sub> nanoparticles 1 day after exposure, while La<sub>2</sub>O<sub>3</sub> nanoparticles induced the greater response 7 days after high-dose exposure. KC/GRO (Fig. 8d) was significantly elevated by CoO nanoparticles at 1 and 7 days after both exposure levels. La<sub>2</sub>O<sub>3</sub> nanoparticle induced KC/GRO expression at 1 and 7 days after both exposure levels and at 56 days after the high exposure compared to air control. When comparing the particle responses, low-dose La<sub>2</sub>O<sub>3</sub> nanoparticles induced greater KC/GRO expression than CoO nanoparticles at 1 and 7 days post exposure, as well as at all time points after high-dose exposure. Taken together, these data suggest that the different expression patterns of pro-inflammatory cytokines and chemokines in the BALF of mice exposed to CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles may lead to different modes of pulmonary damage and inflammation.

**Histopathology**


Mouse lungs were analyzed histologically after animal sacrifices on days 1, 7, and 56 following low and high-dose exposures to both particle types. There were no significant pathological changes observed at low exposure levels (data not shown). However, after high-dose exposure, we observed an increase in the number of alveolar macrophages in response to CoO nanoparticles inhalation at 1 and 7 days post exposure, which returned to air-only control levels by day 56. In contrast, the number of alveolar macrophages in lungs of La<sub>2</sub>O<sub>3</sub> nanoparticle-exposed mice increased progressively from day 1 to day 7 post exposure and remained elevated for up to 56 days post exposure (Fig. 10).

There was no prominent interstitial fibrosis observed in the lungs of animals exposed to CoO nanoparticles 56 days after inhalation exposure. In contrast, minimal fibrosis was occasionally seen in the lungs of animals exposed to La<sub>2</sub>O<sub>3</sub> nanoparticles 56 days post exposure (Fig. 11). This fibrosis was localized to areas of inflammation, suggesting collagen deposition at sites of macrophage activation and cytokine release. Infrequent observations in the lung tissue of the La<sub>2</sub>O<sub>3</sub> nanoparticle-exposed animals, included epithelial hyperplasia of bronchioles and alveoli, vasculitis



**Fig. 10** Histopathology. Lungs of mice exposed to 30 mg /m<sup>3</sup> CoO or La<sub>2</sub>O<sub>3</sub> nanoparticles or air control were stained with H&E. n = 12 mice per group





**Fig. 11** Interstitial fibrosis in lungs of  $\text{La}_2\text{O}_3$  nanoparticle-exposed mice. Higher power magnification and Picrosirius red (PSR) staining demonstrate a small focus of interstitial fibrosis in a  $\text{La}_2\text{O}_3$  nanoparticles exposed animal at 56 days post exposure.  $n = 12$  male mice per group

(data not shown), and pleural fibrosis (Fig. 11). There were no observable differences seen in the lungs of CoO nanoparticle-exposed mice at 56 day post exposure compared to air control (data not shown).

## Discussion

The present study determined pulmonary responses to inhalation exposure to CoO and  $\text{La}_2\text{O}_3$  nanoparticles. Exposures were 6 h/day for 4 days to  $10 \text{ mg/m}^3$  or  $30 \text{ mg/m}^3$ . Lung burden was measured at 1 h and 56 days post-exposure to evaluate clearance. Bronchoalveolar lavage was conducted to evaluate lung damage (LDH) and inflammation (cell differentials and cytokines) at 1, 7, and 56 days after inhalation exposure. Enhanced darkfield microscopy was conducted at 1 and 56 days post exposure to determine initial deposition and time-dependent translocation of the nanoparticles. Histopathologic analysis determined the degree of pulmonary inflammation and fibrosis at 1, 7, and 56 days after inhalation exposure to these nanoparticles.

Inhalation of CoO nanoparticles resulted in acute pulmonary damage and inflammation with BAL levels of LDH and inflammatory mediators peaking at 1 day post-exposure (Figs. 7 and 8). Likewise histopathologic results indicate an alveolar macrophage inflammatory response, which peaked at 1 day after inhalation of CoO nanoparticles (Fig. 10). In contrast, pulmonary responses to inhalation of  $\text{La}_2\text{O}_3$  nanoparticles were more persistent than after CoO nanoparticles exposure. Indeed, LDH activity of BALF and levels of inflammatory mediators peaked at 7 days post exposure (Figs. 7 and 8), and histopathology indicated that mild histiocytosis was found in  $\text{La}_2\text{O}_3$  nanoparticle-exposed lungs at 56 days

after inhalation exposure. In addition,  $\text{La}_2\text{O}_3$  nanoparticles exposure resulted in a mild fibrotic response (Fig. 11).

In summary, the present data concerning pulmonary responses 56 days after in vivo exposure suggest that inhalation exposure to  $\text{La}_2\text{O}_3$  nanoparticles was more fibrogenic and caused more persistent inflammation than CoO nanoparticles at equivalent aerosol exposure levels. In comparison, our previous in vitro assays of cytotoxicity and induction of oxidative stress reported that CoO nanoparticles were substantially more potent than  $\text{La}_2\text{O}_3$ , supporting predictions from band gap theory [3, 7]. Additionally, our short term (1 day post) oropharyngeal aspiration study in mice reported that CoO nanoparticles caused a greater acute inflammatory response, supporting the conclusion from in vitro studies [3]. It is likely that differences between our previous in vitro and acute (1 day post exposure) in vivo studies and those of the present longer term (56 day post-exposure) 4 day inhalation exposure study are due to differences in the clearance rates for these two nanoparticles. Measurement of lung burdens 1 h after the end of the 4 day inhalation exposure indicate that burdens for CoO nanoparticles were only 25 % of those for  $\text{La}_2\text{O}_3$  nanoparticles at both the low ( $10 \text{ mg/m}^3$ ) and high ( $30 \text{ mg/m}^3$ ) exposure levels, i.e., lung burdens of 7.7 and  $18.7 \mu\text{g}$  vs. 30.1 and  $77.5 \mu\text{g}$  for CoO and  $\text{La}_2\text{O}_3$  nanoparticles, respectively. These differences in lung burdens at the start of the post exposure observation period would not have been predicted by the lung deposition vs particle aerodynamic diameter data reported by Raabe et al. [18] for mice, since aerosol levels and mass median aerodynamic diameters (MMADs) for CoO and  $\text{La}_2\text{O}_3$  nanoparticles were nearly identical for these inhalation exposures (Fig. 1). Of note,

estimations from the Raabe et al. data predicts that as high as 60 % of lung deposition of particles with MMADs of 2  $\mu\text{m}$  would be in the tracheobronchiolar region of the mouse lung, with the remaining 40 % depositing in the alveolar region of the lung [18]. Enhanced darkfield microscopy at 1 day post exposure indicates that CoO nanoparticles were rapidly cleared from the conducting airways during the 4 day inhalation period by the mucociliary escalator, which exhibits a half time for clearance of a few hours. However, enhanced darkfield microscopy indicates that 1 day after inhalation exposure the La nanoparticles had translocated from the surface of the conducting airways into bronchial epithelial cells (Fig. 5c), thus, escaping mucociliary clearance. This emphasizes that calculated lung deposition does not always reflect actual particle lung burdens, and that measurement of lung burden is essential to correctly interpret pulmonary response. Our previous *in vitro* [7] and 1 day post-aspiration *in vivo* [3] studies would not be able to discern this clearance-dependent difference in initial lung burden of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles; thus, they would fail to predict the greater sub-chronic inflammatory and fibrogenic potential of La<sub>2</sub>O<sub>3</sub> vs. CoO nanoparticles found in the present study.

As discussed above, lung burden 1 h after the 4 day exposure was greater for La than Co metal oxide nanoparticles, reflecting predominant rapid clearance of CoO nanoparticles by the mucociliary escalator. Concerning the slow phase of clearance, whole lung burden for La nanoparticles was also greater than that for CoO nanoparticles at 56 days post-exposure, where persistent whole lung burden was 6.6  $\mu\text{g}$  and 38.8  $\mu\text{g}$  for the low and high level of La<sub>2</sub>O<sub>3</sub> nanoparticles, respectively, compared to < 1 % of the 1 h post exposure lung burden for CoO nanoparticles. There are two different slow pulmonary clearance mechanisms: 1) uptake of the nanoparticles deposited in the respiratory zone by alveolar macrophages and slow migration of these particle-laden cells to the mucociliary escalator, or 2) translocation of the nanoparticles across epithelial cells into the interstitium and slow clearance through the lymphatic system [19]. Upon analyzing the enhanced darkfield images, the CoO nanoparticles deposited in the respiratory zone were seen mainly in alveolar macrophages at 1 day post-exposure, suggesting slow clearance via migration to the mucociliary escalator (Fig. 3). However, a large amount of the La nanoparticles were seen in epithelial cells and the interstitium of the airways at 1 day post exposure (Figs. 3 and 5) and in the lymphatic system by 56 days post exposure (Fig. 4). In contrast, very few CoO nanoparticles were detected in the tracheobronchial lymph nodes of exposed mice at 56 days post inhalation. The difference in pulmonary fate and clearance mechanism for Co and La nanoparticles would result in the

observed differences in pulmonary responses reported in the present study.

Mechanistic non-animal studies do shed light upon the results of the present mouse inhalation study. For example, we have reported that La<sub>2</sub>O<sub>3</sub> nanoparticles were present within phagolysosomes of differentiated THP-1 macrophages after a 6 h exposure in culture [6]. Additionally, we showed that La<sub>2</sub>O<sub>3</sub> nano-spheres transform into sea urchin-shaped LaPO<sub>4</sub> particles after a 24 h incubation in an acidic PSF, and such sea urchin-shaped particles were found in the differentiated THP-1 macrophages 12 h after *in vitro* exposure to La<sub>2</sub>O<sub>3</sub> nanoparticles. Associated with this transformation of La nanoparticles was rupture of lysosomal membranes, demonstrated by the cytosolic release of cathepsin B into the cytoplasm of differentiated THP-1 macrophages 12 h after *in vitro* exposure to La<sub>2</sub>O<sub>3</sub> nanoparticles [6]. Our lab has also shown that rupture of lysosomes in alveolar macrophages was observed 40 h after exposure of mice by aspiration of La<sub>2</sub>O<sub>3</sub> nanoparticles [6]. Therefore, it is feasible that in the present inhalation study that La<sub>2</sub>O<sub>3</sub> nanoparticles were transformed upon engulfment by alveolar macrophages, ruptured phagolysosomes, escaped these phagocytes, and entered bronchial epithelial cells, thus, avoiding clearance by the mucociliary escalator. CoO nanoparticles, in contrast to La<sub>2</sub>O<sub>3</sub>, did not undergo such transformation, since they did not lyse lysosomes (Fig. 9). Therefore, CoO nanoparticles would remain in macrophages and be cleared.

Mechanistic *in vitro* studies also predict the fibrotic response to La<sub>2</sub>O<sub>3</sub> nanoparticles exposure observed in the present inhalation study. Indeed, Fig. 9b shows that *in vitro* exposure of THP-1 macrophages to La<sub>2</sub>O<sub>3</sub> nanoparticles for 6 h activated the NLRP3 inflammasome as indicated by a substantial, dose-dependent release of IL-1 $\beta$  with La<sub>2</sub>O<sub>3</sub> nanoparticles, while CoO nanoparticles failed to induce IL-1 $\beta$  production. Activation of the NLRP3 inflammasome has been linked with pulmonary fibrotic diseases, such as silicosis and asbestosis [20, 21]. In addition, IL-1 $\beta$  has been shown to activate fibroblasts and cause pulmonary fibrotic responses [22–24]. The present study indicates that inhalation of La<sub>2</sub>O<sub>3</sub> nanoparticles caused a 9 fold greater IL-1 $\beta$  production 7 days after inhalation than the non-fibrotic CoO nanoparticles inhalation (Fig. 8a).

Of interest, our longer term (21 day post exposure) aspiration study in mice did observe NLRP3 inflammasome activation (2.4 fold increase in BALF levels of IL-1 $\beta$ ) and pulmonary fibrosis in response to La<sub>2</sub>O<sub>3</sub> nanoparticles [6]. This indicates that when lung burdens are similar, results of bolus particle exposure studies can be predictive of more costly and technically more complex inhalation studies. Therefore, there is an important role for pulmonary bolus exposure studies (oropharyngeal aspiration and intratracheal instillation) in a tiered

approach to hazard ranking and assessment for nanoparticles.

In addition to IL-1 $\beta$ , other mediators have been associated with fibrogenesis. TNF- $\alpha$  has been demonstrated to play a key role in activating molecular pathways leading to pulmonary fibrosis [25–27]. In the present study, we found that La<sub>2</sub>O<sub>3</sub> nanoparticles inhalation at 30 mg/m<sup>3</sup> caused a 6 fold greater production of TNF- $\alpha$  than CoO nanoparticles at 7 days post exposure (Fig. 8b). Previously, we reported that aspiration of La<sub>2</sub>O<sub>3</sub> nanoparticles induced a 2 fold increase in BALF levels of TGF- $\beta$ 1 and PDGF, mediators associated with pulmonary fibrogenesis, 21 days post exposure in mice [6]. This was associated with a 67 % increase in lung collagen.


In the present study, the lung burden of La<sub>2</sub>O<sub>3</sub> nanoparticles 1 h after a 4 day inhalation of 30 mg/m<sup>3</sup> was 77.5  $\mu$ g/whole lung. In our previous oropharyngeal aspiration study, lung burden was 50  $\mu$ g/lung [6]. It should be noted that such lung burdens are lower than those necessary to cause volumetric overload and impairment of clearance [28]. Indeed, alveolar macrophages were not overloaded with particles (Fig. 3), and inhalation of an equal aerosol exposure dose of CoO nanoparticles did not result in delayed clearance.

An issue is the relevance of these pulmonary doses of La<sub>2</sub>O<sub>3</sub> nanoparticles to expected worker exposure. Unfortunately, no worker exposure data for nano-La<sub>2</sub>O<sub>3</sub> are available. To date, the only Recommended Exposure Limit (REL) for a nano metal oxide is 0.3 mg/m<sup>3</sup> proposed for nano TiO<sub>2</sub> [29]. Assuming this level of airborne La<sub>2</sub>O<sub>3</sub>

nanoparticles in a workplace, workers would be expected to achieve a lung burden, normalized to an equivalent burden per lung surface area, similar to the mice in these studies in approximately 1 year. Therefore, our studies are relevant to feasible worker exposure.

In the present study, the physical chemical transformation of La<sub>2</sub>O<sub>3</sub> nanospheres to LaPO<sub>4</sub> urchin-shaped particles is proposed to be related to the interstitial accumulation of La and fibrosis. Of interest, it has recently been reported that CeO<sub>2</sub> transforms into urchin-shaped phosphate Ce nanoparticles in vivo [30]. This may explain why CeO<sub>2</sub> nanoparticles exhibit low in vitro cytotoxicity, yet induce pulmonary fibrosis in a rat model [31]. In light of these findings, further investigation into the phosphation of certain nano metal oxides and resultant alterations in the bioactivity of these transformed particles is warranted.

We have proposed high throughput in vitro screening as an essential component of a tiered testing approach for nanoparticles [11]. Prudent selection of in vitro assays to identify adverse outcome pathways (AOPs) produces potency and mechanistic data in a rapid and low cost manner. Such data can be used for hazard ranking. In addition, in vitro testing can provide guidance concerning which in vivo responses to evaluate. We do not propose use of in vitro data for quantitative risk assessment, since in vitro assays use doses/cell surface area much higher than dose anticipated in the human lung per alveolar epithelial surfaces area. However, when carefully conducted, in vitro results have been able to



**Fig. 12** Schematic image showing the toxicity mechanisms of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles. The redox potential of CoO nanoparticles falls into the biological redox potential (BRP), which allows electrons to transfer from biological molecules to CoO nanoparticles. This process could induce oxidative stress, leading to mitochondria damage, cell death and acute lung toxicity. In contrast, no electrons were transferred from biological system to La<sub>2</sub>O<sub>3</sub> nanoparticles. However, La<sub>2</sub>O<sub>3</sub> nanoparticles could transform into sea urchin LaPO<sub>4</sub> in lysosomes, induce lysosomal damage, cathepsin B release, NLRP3 inflammasome activation and IL-1 $\beta$  production, which finally results in chronic lung inflammation and fibrosis

predict in vivo response to nanoparticles, such as carbon nanotubes and metal oxides [6, 32]. In the present study, doses/culture cell surface area were much higher than lung burdens normalized to the alveolar surface in the mouse. However, in vitro studies did produce mechanistic information useful to interpret the differences in clearance of fibrotic responses of mice after inhalation of CoO and La<sub>2</sub>O<sub>3</sub> nanoparticles.

## Conclusion

In summary, results from the present study as well as previous studies indicate that a tiered approach is required to predict sub-chronic responses following inhalation of CoO or La<sub>2</sub>O<sub>3</sub> nanoparticles. Simple in vitro assays for oxidative stress and cell death predict the acute inflammatory response to CoO nanoparticles in agreement with the band gap theory. However, they do not explain the persistent whole lung burden and fibrotic response after inhalation of La<sub>2</sub>O<sub>3</sub> nanoparticles. More mechanistic in vitro assays associated with bio-transformation of La<sub>2</sub>O<sub>3</sub> nanoparticles to LaPO<sub>4</sub> and activation of the NLRP3 inflammasome do shed light on the biopersistent and fibrogenic potential of La<sub>2</sub>O<sub>3</sub> nanoparticles. Lastly, bolus pulmonary exposure studies involving La<sub>2</sub>O<sub>3</sub> nanoparticles were able to predict the fibrogenic response seen after inhalation exposure, when similar exposure doses and post exposure times are employed. This tiered approach employing relevant adverse outcome pathways for hazard assessment is summarized in Fig. 12.

## Additional file

**Additional file 1: Figure S1.** Detection of ROS production in nanoparticle suspensions. The oxidative radicals were determined in free cell media (RPMI 1640 supplemented with 10 % serum), 100 µg/mL nanoparticle suspensions by incubating with 25 µg/mL H<sub>2</sub>DCF solutions. After a 2 h incubation at room temperature, the DCF fluorescence was excited at 490 nm and detected at 520 nm. (TIF 14972 kb)

## Acknowledgements

"Not Applicable".

## Funding

The work by UCLA was primarily supported by the U.S. Public Health Service Grant, R01 ES016746, with also leveraged infrastructure support from the National Science Foundation and the Environmental Protection Agency under Cooperative Agreement Number DBI 0830117 and 1266377. The WVU Flow Cytometry & Single Cell Core was supported by the following grants: MBRCC CoBRE grant: GM103488/RR032138, ARIA S10 grant: RR020866, C1 Single Cell Prep System WV CTR grant: GM104942, Fortess S10 grant: OD016165 and WV InBRE grant: GM103434.

## Availability of data and material

The datasets analyzed during this study will be made available from the corresponding author upon a reasonable request.

## Authors' contributions

JDS designed and performed all in vivo experiments. RL, ZJ, TX, and XW designed and performed in vitro assays. WM designed and performed the

whole-body inhalation exposure. RRM performed enhanced darkfield analysis of samples. JS, ALM, LB, MW and DSB helped with in vivo experiments. MO performed histopathology analysis. BTC performed exposure chamber calculations and experimental design for whole-body inhalation exposures. MEA performed statistical analysis. DWP, VC, AN, and YQ contributed intellectually to the project design and in writing the manuscript. All authors read and approved the final manuscript.

## Competing interest

The authors declare that they have no competing interests.

## Consent for publication

"Not Applicable."

## Ethics approval

All procedures performed on animals were approved by the NIOSH Institutional Animal Care and Use Committee (IACUC).

## Disclaimer

The findings and conclusions in this report are of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.

## Author details

<sup>1</sup>Health Effects Laboratory Division, National Institute for Occupational Safety and Health, 1095 Willowdale Road, Morgantown, WV 26505, USA.

<sup>2</sup>Department of Pharmaceutical Sciences, West Virginia University, Morgantown, WV 26506, USA. <sup>3</sup>Division of NanoMedicine, Department of Medicine, University of California, 10833 Le Conte Ave, Los Angeles, CA 90095, USA. <sup>4</sup>Center for Environmental Implications of Nanotechnology, University of California, Los Angeles, CA 90095, USA. <sup>5</sup>California NanoSystems Institute, University of California, 570 Westwood Plaza, Los Angeles, CA 90095, USA. <sup>6</sup>School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.

Received: 25 March 2016 Accepted: 5 August 2016

Published online: 15 August 2016

## References

- Xie H, Mason MM, Wise Sr JP. Genotoxicity of metal nanoparticles. *Rev Environ Health*. 2011;26(4):251–68.
- McNeilly JD, et al. Soluble transition metals cause the pro-inflammatory effects of welding fumes in vitro. *Toxicol Appl Pharmacol*. 2004;196(1):95–107.
- Zhang H, et al. Use of metal oxide nanoparticle band gap to develop a predictive paradigm for oxidative stress and acute pulmonary inflammation. *ACS Nano*. 2012;6(5):4349–68.
- Burello E, Worth AP. QSAR modeling of nanomaterials. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2011;3(3):298–306.
- Burello E, Worth AP. A theoretical framework for predicting the oxidative stress potential of oxide nanoparticles. *Nanotoxicology*. 2011;5(2):228–35.
- Li R, et al. Surface interactions with compartmentalized cellular phosphates explain rare earth oxide nanoparticle hazard and provide opportunities for safer design. *ACS Nano*. 2014;8(2):1771–83.
- Sisler JD, et al. Toxicological Assessment of CoO and La<sub>2</sub>O<sub>3</sub> Metal Oxide Nanoparticles in Human Small Airway Epithelial Cells. *Toxicol Sci*. 2016; 150(2):418–28.
- Chattopadhyay S, et al. Toxicity of cobalt oxide nanoparticles to normal cells; an in vitro and in vivo study. *Chem Biol Interact*. 2015;226:58–71.
- Verstraelen S, et al. Gene expression profiles reveal distinct immunological responses of cobalt and cerium dioxide nanoparticles in two in vitro lung epithelial cell models. *Toxicol Lett*. 2014;228(3):157–69.
- Lim CH. Toxicity of Two Different Sized Lanthanum Oxides in Cultured Cells and Sprague-Dawley Rats. *Toxicol Res*. 2015;31(2):181–9.
- Nel A, et al. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. *Acc Chem Res*. 2013;46(3):607–21.
- McKinney W, et al. Computer-automated silica aerosol generator and animal inhalation exposure system. *Inhal Toxicol*. 2013;25(7):363–72.



13. McKinney W, et al. Pulmonary and cardiovascular responses of rats to inhalation of a commercial antimicrobial spray containing titanium dioxide nanoparticles. *Inhal Toxicol.* 2012;24(7):447–57.
14. Mercer RR, et al. Distribution and fibrotic response following inhalation exposure to multi-walled carbon nanotubes. *Part Fibre Toxicol.* 2013;10:33.
15. Mercer RR, et al. Extrapulmonary transport of MWCNT following inhalation exposure. *Part Fibre Toxicol.* 2013;10:38.
16. Ma J, et al. Effects of amorphous silica coating on cerium oxide nanoparticles induced pulmonary responses. *Toxicol Appl Pharmacol.* 2015; 288(1):63–73.
17. Littell RC, W.W. S, Freund RJ. *SAS for Linear Models.* Cary: SAS Institute; 2002.
18. Raabe OG, M.A.A. B, Teague SV, Rasolt A. Regional Deposition of Inhaled Monodisperse Coarse and Fine Aerosol Particles in Small Laboratory Animals. *Ann Occup Hyg.* 1988;32:53–63.
19. Ferin J, Oberdörster G. Translocation of Particles from Pulmonary Alveoli into the Interstitium. *Journal of Aerosol Medicine.* 1992;5(3):179–87.
20. Peeters PM, et al. Silica-induced NLRP3 inflammasome activation in vitro and in rat lungs. *Part Fibre Toxicol.* 2014;11:58.
21. Dostert C, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. *Science.* 2008;320(5876):674–7.
22. Kolb M, et al. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. *J Clin Invest.* 2001;107(12): 1529–36.
23. Lindroos PM, et al. Alveolar macrophages stimulated with titanium dioxide, chrysotile asbestos, and residual oil fly ash upregulate the PDGF receptor-alpha on lung fibroblasts through an IL-1beta-dependent mechanism. *Am J Respir Cell Mol Biol.* 1997;16(3):283–92.
24. Birrell M, et al. Effect of the p38 kinase inhibitor, SB 203580, on sephadex induced airway inflammation in the rat. *Eur Respir J.* 2000;16(5):947–50.
25. Gwyer Findlay E, Hussell T. Macrophage-mediated inflammation and disease: a focus on the lung. *Mediators Inflamm.* 2012;2012:140937.
26. Piguet PF. Is "tumor necrosis factor" the major effector of pulmonary fibrosis? *Eur Cytokine Netw.* 1990;1(4):257–8.
27. Piguet PF, et al. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. *Nature.* 1990;344(6263):245–7.
28. Morrow PE. Possible mechanisms to explain dust overloading of the lungs. *Fundam Appl Toxicol.* 1988;10(3):369–84.
29. NIOSH, Current Intelligence Bulletin 63: Occupational Exposure to Titanium Dioxide. Washington DC: DHHS (NIOSH); 2011. 2011–160.
30. Graham, U. Fate of cerium ions in the lungs: in vivo formation of cerium phosphate nanoparticles from instilled cerium chloride. in 8th International Nanotoxicology Congress. Boston, MA. 2016.
31. Ma JY, et al. Induction of pulmonary fibrosis by cerium oxide nanoparticles. *Toxicol Appl Pharmacol.* 2012;262(3):255–64.
32. Li R, et al. Surface charge and cellular processing of covalently functionalized multiwall carbon nanotubes determine pulmonary toxicity. *ACS Nano.* 2013;7(3):2352–68.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

